Cidara Therapeutics (CDTX) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 18, 2025, with voting open until June 17, 2025 at 11:59 PM ET.

• Shareholders can access proxy materials online or request paper/email copies by June 4, 2025.

• Meeting will be held virtually, allowing remote participation and voting.

Voting matters and shareholder proposals

• Election of three Class I directors: Jeffrey Stein, Ph.D., Bonnie Bassler, Ph.D., and Ryan Spencer, all recommended by the board.

• Proposal to amend the certificate of incorporation to increase authorized common stock from 50,000,000 to 100,000,000 shares.

• Amendment to the 2024 Equity Incentive Plan up for approval.

• Advisory vote on executive compensation (say-on-pay) included.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2025.

Board of directors and corporate governance

• Board recommends all director nominees for election.

• Board's Audit Committee responsible for auditor selection.